Publications scientifiques en 2016

Depuis le 02/06/2023

  1. Comparison of two drug safety signals in a pharmacovigilance data mining framework.
    Tubert-Bitter P, Bégaud B, Ahmed I.
    Stat Methods Med Res. 2016
  2. Sudden cardiac and sudden unexpected death related to antipsychotics: A meta-analysis of observational studies.
    Salvo F, Pariente A, Shakir S, Robinson P, Arnaud M, Thomas S, Raschi E, Fourrier-R?glat A, Moore N, Sturkenboom M, Hazell On Behalf Of Investigators Of The Aritmo Consortium L; Investigators of the ARITMO Consortium.
    Clin Pharmacol Ther. 2016
  3. Secondary Metastases Resection After Bevacizumab Plus Irinotecan-Based Chemotherapy in First-Line Therapy of Metastatic Colorectal Cancer in a Real-Life Setting: Results of the ETNA Cohort.
    Rouyer M, Smith D, Laurent C, Becouarn Y, Guimbaud R, Michel P, Tubiana-Mathieu N, Balestra A, Jov? J, Robinson P, Noize P, Moore N, Ravaud A, Fourrier-R?glat A; ETNA study group.
    Target Oncol. 2016
  4. Patterns and effectiveness of bortezomib use according to age in the VESUVE cohort.
    Grelaud A, Fourrier-Réglat A, Fitoussi O, Facon T, Jové J, Bénichou J, Robinson P, Marit G, Rouyer M, Moore N, Noize P; VESUVE Study Group.
    Leuk Lymphoma. 2016
  5. The Contribution of National Spontaneous Reporting Systems to Detect Signals of Torsadogenicity: Issues Emerging from the ARITMO Project.
    Raschi E, Poluzzi E, Salvo F, Koci A, Suling M, Antoniazzi S, Perina L, Hazell L, Moretti U, Sturkenboom M, Garbe E, Pariente A, De Ponti F.
    Drug Saf. 2016
  6. A population database study of outcomes associated with vitamin K antagonists in atrial fibrillation before DOAC.
    Blin P, Dureau-Pournin C, Lassalle R, Abouelfath A, Droz-Perroteau C, Moore N.
    Br J Clin Pharmacol. 2016
  7. Compliance of psychotropic drug prescription with clinical practice guidelines in older inpatients.
    Etchepare F, Pambrun E, Bégaud B, Verdoux H, Tournier M.
    Fundam Clin Pharmacol. 2016
  8. Evolution and Determinants of Health-Related Quality-of-Life in Kidney Transplant Patients Over the First 3 Years After Transplantation.
    Villeneuve C, Laroche ML, Essig M, Merville P, Kamar N, Coubret A, Lacroix I, Bouchet S, Fruit D, Marquet P, Rousseau A; EPIGREN study group.
    Transplantation. 2016
  9. Vitamin K Antagonists and Cognitive Function in Older Adults: The Three-City Cohort Study.
    Ferland G, Feart C, Presse N, Lorrain S, Bazin F, Helmer C, Berr C, Annweiler C, Rouaud O, Dartigues JF, Fourrier-Reglat A, Barberger-Gateau P.
    J Gerontol A Biol Sci Med Sci. 2016
  10. [Benefits and risks for primary prevention with statins in the elderly].
    Joseph JP, Afonso M, Berdaï D, Salles N, B?nard A, Gay B, Bonnet F.
    Presse Med. 2016
  11. Benzodiazepine, psychotropic medication, and dementia: A population-based cohort study.
    Shash D, Kurth T, Bertrand M, Dufouil C, Barberger-Gateau P, Berr C, Ritchie K, Dartigues JF, Bégaud B, Alpérovitch A, Tzourio C.
    Alzheimers Dement. 2016
  12. Illicit drugs or medicines taken by parachuting.
    Daveluy A, Géniaux H, Eiden C, Boucher A, Chenaf C, Deheul S, Spadari M, Gérardin M, Miremont-Salamé G, Haramburu F; French Network of Addictovigilance Centres.
    Fundam Clin Pharmacol. 2016
  13. The Benzodiazepine-Dementia Disorders Link: Current State of Knowledge.
    Pariente A, de Gage SB, Moore N, Bégaud B.
    CNS Drugs. 2016
  14. A Method for the Minimization of Competition Bias in Signal Detection from Spontaneous Reporting Databases.
    Arnaud M, Salvo F, Ahmed I, Robinson P, Moore N, Bégaud B, Tubert-Bitter P, Pariente A.
    Drug Saf. 2016
  15. Comparison of serious inhaler technique errors made by device-na??ve patients using three different dry powder inhalers: a randomised, crossover, open-label study.
    Chrystyn H, Price DB, Molimard M, Haughney J, Bosnic-Anticevich S, Lavorini F, Efthimiou J, Shan D, Sims E, Burden A, Hutton C, Roche N.
    BMC Pulm Med. 2016
  16. Effect of esomeprazole on the oral absorption of dasatinib in a patient with Philadelphia-positive acute lymphoblastic leukemia.
    Pape E, Michel D, Scala-Bertola J, Schiestel T, Harlé A, Bouchet S, Contet A, Pochon C, Gambier N.
    Br J Clin Pharmacol. 2016
  17. Relationship between imatinib trough concentration and outcomes in the treatment of advanced gastrointestinal stromal tumours??in a real-life setting.
    Bouchet S, Poulette S, Titier K, Moore N, Lassalle R, Abouelfath A, Italiano A, Chevreau C, Bompas E, Collard O, Duffaud F, Rios M, Cupissol D, Adenis A, Ray-Coquard I, Bouché O, Le Cesne A, Bui B, Blay JY, Molimard M.
    Eur J Cancer. 2016
  18. A candidate gene approach of the calcineurin pathway to identify variants associated with clinical outcomes in renal transplantation.
    Pouché L, Koitka M, Stojanova J, Woillard JB, Monchaud C, Villeneuve C, Essig M, Abraham J, Le Meur Y, Rerolle JP, Kamar N, Rostaing L, Merville P, Gandia P, Bouchet S, Petersen BS, Marquet P, Picard N.
    Pharmacogenomics. 2016
  19. Authors' Reply to Alain Braillon's Comment on "The Contribution of National Spontaneous Reporting Systems to Detect Signals of Torsadogenicity: Issues Emerging from the ARITMO Project".
    Raschi E, Poluzzi E, Salvo F, Moretti U, De Ponti F.
    Drug Saf. 2016
  20. Signal of Gastrointestinal Congenital Malformations with Antipsychotics After Minimising Competition Bias: A Disproportionality Analysis Using Data from Vigibase®.
    Montastruc F, Salvo F, Arnaud M, Bégaud B, Pariente A.
    Drug Saf. 2016
  21. Does paracetamol still have a future in osteoarthritis?
    Moore N, Salvo F, Duong M, Gulmez SE.
    Lancet. 2016
  22. Comorbidities and concurrent medications increasing the risk of adverse drug reactions: prevalence in French benzodiazepine users.
    Bénard-Laribière A, Noize P, Pambrun E, Bazin F, Verdoux H, Tournier M, Bégaud B, Pariente A.
    Eur J Clin Pharmacol. 2016
  23. A diagnostic approach that may help to discriminate inherited thrombocytopenia from chronic immune thrombocytopenia in adult patients.
    Fiore M, Pillois X, Lorrain S, Bernard MA, Moore N, Sié P, Viallard JF, Nurden P.
    Platelets. 2016
  24. Atropinic (Anticholinergic) Burden in Parkinson's Disease.
    De Germay S, Montastruc JL, Rousseau V, Chebane L, Bondon-Guitton E, Moulis F, Durrieu G, Bagheri H, Rascol O, Pariente A, Bégaud B, Montastruc F.
    Mov Disord. 2016
  25. Usage patterns of single-ingredient and combined paracetamol in France.
    Duong M, Gulmez SE, Salvo F, Abouelfath A, Lassalle R, Droz C, Blin P, Moore N.
    Br J Clin Pharmacol. 2016
  26. Risk assessment of drug-induced drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome: a disproportionality analysis using the French Pharmacovigilance Database.
    Agier MS, Boivin N, Maruani A, Giraudeau B, Gouraud A, Haramburu F, Jean Pastor MJ, Machet L, Jonville-Bera AP.
    Br J Dermatol. 2016
  27. Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial.
    Mir O, Cropet C, Toulmonde M, Cesne AL, Molimard M, Bompas E, Cassier P, Ray-Coquard I, Rios M, Adenis A, Italiano A, Bouché O, Chauzit E, Duffaud F, Bertucci F, Isambert N, Gautier J, Blay JY, Pérol D; PAZOGIST study group of the French Sarcoma Groupe-Groupe d'Etude des Tumeurs Osseuses (GSF-GETO).
    Lancet Oncol. 2016
  28. Imputabilité en pharmacovigilance : de la méthode française originelle aux méthodes réactualisées.
    Miremont-Salamé G, Théophile H, Haramburu F, Bégaud B.
    Therapie. 2016
  29. Causality assessment in pharmacovigilance: The French method and its successive updates.
    Miremont-Salamé G, Théophile H, Haramburu F, Bégaud B.
    Therapie. 2016
  30. L'apport de la pharmaco-épidémiologie à la pharmacovigilance.
    Faillie JL, Montastruc F, Montastruc JL, Pariente A.
    Therapie. 2016
  31. Pharmacoepidemiology and its input to pharmacovigilance.
    Faillie JL, Montastruc F, Montastruc JL, Pariente A.
    Therapie. 2016
  32. Effectiveness and safety of first-line bevacizumab plus FOLFIRI in elderly patients with metastatic colorectal cancer: Results of the ETNA observational cohort.
    Rouyer M, Fourrier-Réglat A, Smith D, Becouarn Y, Guimbaud R, Tubiana-Mathieu N, Robinson P, Jové J, Grelaud A, Noize P, Moore N, Ravaud A.
    J Geriatr Oncol. 2016
  33. Class-imbalanced subsampling lasso algorithm for discovering adverse drug reactions.
    Ahmed I, Pariente A, Tubert-Bitter P.
    Stat Methods Med Res. 2016
  34. Addition of dipeptidyl peptidase-4 inhibitors to sulphonylureas and risk of hypoglycaemia: systematic review and meta-analysis.
    Salvo F, Moore N, Arnaud M, Robinson P, Raschi E, De Ponti F, Bégaud B, Pariente A.
    BMJ. 2016
  35. Homeopathic medical practice for anxiety and depression in primary care: the EPI3 cohort study.
    Grimaldi-Bensouda L, Abenhaim L, Massol J, Guillemot D, Avouac B, Duru G, Lert F, Magnier AM, Rossignol M, Rouillon F, Bégaud B; EPI3-LA-SER group.
    BMC Complement Altern Med. 2016
  36. Safety Meta-Analysis: A Call for Appropriate Use of Disproportionality Measures From Spontaneous Reporting Systems.
    Raschi E, Salvo F, Poluzzi E, De Ponti F.
    J Am Coll Cardiol. 2016
  37. Lessons from the fatal French study BIA-10-2474.
    Moore N.
    BMJ. 2016
  38. Authors' reply to Tufan and colleagues and Boucaud-Maitre.
    Salvo F, Moore N, Arnaud M, Robinson P, Raschi E, De Ponti F, Bégaud B, Pariente A.
    BMJ. 2016
  39. Serious adverse drug events related to non-investigational drugs in academic clinical trials: another source of safety data for risk assessment?
    Olivier P, Gimbert A, Colin AL, Salvo F, Becker M, Marty V, Montastruc JL, Petitpain N.
    Br J Clin Pharmacol. 2016
  40. Patterns of selective serotonin reuptake inhibitor use and risk of falls and fractures in community-dwelling elderly people: the Three-City cohort.
    Carrière I, Farré A, Norton J, Wyart M, Tzourio C, Noize P, Pérès K, Fourrier-Réglat A, Ancelin ML.
    Osteoporos Int. 2016
  41. [The current aspects of the use of ecstasy/MDMA in France]
    Spadari M, Batisse A, Guerlais M, Boucher A, Daveluy A, Le Boisselier R, Gibaja V, Eiden C, Lepelley M, Roussin A, Deheul S, Frauger E, Debruyne D.
    Therapie. 2016
  42. Outcomes following acute hospitalised myocardial infarction in France: An insurance claims database analysis.
    Blin P, Philippe F, Bouée S, Laurendeau C, Torreton E, Gourmelin J, Leproust S, Levy-Bachelot L, Steg PG.
    Int J Cardiol. 2016
  43. Mycophenolic Acid Pharmacokinetics and Relapse in Children with Steroid-Dependent Idiopathic Nephrotic Syndrome.
    Tellier S, Dallocchio A, Guigonis V, Saint-Marcoux F, Llanas B, Ichay L, Bandin F, Godron A, Morin D, Brochard K, Gandia P, Bouchet S, Marquet P, Decramer S, Harambat J.
    Clin J Am Soc Nephrol. 2016
  44. Acute Methiopropamine Intoxication After "Synthacaine" Consumption.
    Daveluy A, Castaing N, Cherifi H, Richeval C, Humbert L, Faure I, Labadie M, Allorge D, Haramburu F, Molimard M, Titier K.
    J Anal Toxicol. 2016
  45. Scaling up strategies of the chronic respiratory disease programme of the European Innovation Partnership on Active and Healthy Ageing (Action Plan B3: Area 5).
    Bousquet J, Farrell J, Crooks G, Hellings P, Bel EH, Bewick M, Chavannes NH, de Sousa JC, Cruz AA, Haahtela T, Joos G, Khaltaev N, Malva J, Muraro A, Nogues M, Palkonen S, Pedersen S, Robalo-Cordeiro C, Samolinski B, Strandberg T, Valiulis A, Yorgancioglu A, Zuberbier T, Bedbrook A, Aberer W, Adachi M, Agusti A, Akdis CA, Akdis M, Ankri J, Alonso A, Annesi-Maesano I, Ansotegui IJ, Anto JM, Arnavielhe S, Arshad H, Bai C, Baiardini I, Bachert C, Baigenzhin AK, Barbara C, Bateman ED, Beghé B, Kheder AB, Bennoor KS, Benson M, Bergmann KC, Bieber T, Bindslev-Jensen C, Bjermer L, Blain H, Blasi F, Boner AL, Bonini M, Bonini S, Bosnic-Anticevitch S, Boulet LP, Bourret R, Bousquet PJ, Braido F, Briggs AH, Brightling CE, Brozek J, Buhl R, Burney PG, Bush A, Caballero-Fonseca F, Caimmi D, Calderon MA, Calverley PM, Camargos PA, Canonica GW, Camuzat T, Carlsen KH, Carr W, Carriazo A, Casale T, Cepeda Sarabia AM, Chatzi L, Chen YZ, Chiron R, Chkhartishvili E, Chuchalin AG, Chung KF, Ciprandi G, Cirule I, Cox L, Costa DJ, Custovic A, Dahl R, Dahlen SE, Darsow U, De Carlo G, De Blay F, Dedeu T, Deleanu D, De Manuel Keenoy E, Demoly P, Denburg JA, Devillier P, Didier A, Dinh-Xuan AT, Djukanovic R, Dokic D, Douagui H, Dray G, Dubakiene R, Durham SR, Dykewicz MS, El-Gamal Y, Emuzyte R, Fabbri LM, Fletcher M, Fiocchi A, Fink Wagner A, Fonseca J, Fokkens WJ, Forastiere F, Frith P, Gaga M, Gamkrelidze A, Garces J, Garcia-Aymerich J, Gemicio?lu B, Gereda JE, González Diaz S, Gotua M, Grisle I, Grouse L, Gutter Z, Guzmán MA, Heaney LG, Hellquist-Dahl B, Henderson D, Hendry A, Heinrich J, Heve D, Horak F, Hourihane JO, Howarth P, Humbert M, Hyland ME, Illario M, Ivancevich JC, Jardim JR, Jares EJ, Jeandel C, Jenkins C, Johnston SL, Jonquet O, Julge K, Jung KS, Just J, Kaidashev I, Kaitov MR, Kalayci O, Kalyoncu AF, Keil T, Keith PK, Klimek L, Koffi N'Goran B, Kolek V, Koppelman GH, Kowalski ML, Kull I, Kuna P, Kvedariene V, Lambrecht B, Lau S, Larenas-Linnemann D, Laune D, Le LT, Lieberman P, Lipworth B, Li J, Lodrup Carlsen K, Louis R, MacNee W, Magard Y, Magnan A, Mahboub B, Mair A, Majer I, Makela MJ, Manning P, Mara S, Marshall GD, Masjedi MR, Matignon P, Maurer M, Mavale-Manuel S, Melén E, Melo-Gomes E, Meltzer EO, Menzies-Gow A, Merk H, Michel JP, Miculinic N, Mihaltan F, Milenkovic B, Mohammad GM, Molimard M, Momas I, Montilla-Santana A, Morais-Almeida M, Morgan M, Mösges R, Mullol J, Nafti S, Namazova-Baranova L, Naclerio R, Neou A, Neffen H, Nekam K, Niggemann B, Ninot G, Nyembue TD, O'Hehir RE, Ohta K, Okamoto Y, Okubo K, Ouedraogo S, Paggiaro P, Pali-Schöll I, Panzner P, Papadopoulos N, Papi A, Park HS, Passalacqua G, Pavord I, Pawankar R, Pengelly R, Pfaar O, Picard R, Pigearias B, Pin I, Plavec D, Poethig D, Pohl W, Popov TA, Portejoie F, Potter P, Postma D, Price D, Rabe KF, Raciborski F, Radier Pontal F, Repka-Ramirez S, Reitamo S, Rennard S, Rodenas F, Roberts J, Roca J, Rodriguez Mañas L, Rolland C, Roman Rodriguez M, Romano A, Rosado-Pinto J, Rosario N, Rosenwasser L, Rottem M, Ryan D, Sanchez-Borges M, Scadding GK, Schunemann HJ, Serrano E, Schmid-Grendelmeier P, Schulz H, Sheikh A, Shields M, Siafakas N, Sibille Y, Similowski T, Simons FE, Sisul JC, Skrindo I, Smit HA, Solé D, Sooronbaev T, Spranger O, Stelmach R, Sterk PJ, Sunyer J, Thijs C, To T, Todo-Bom A, Triggiani M, Valenta R, Valero AL, Valia E, Valovirta E, Van Ganse E, van Hage M, Vandenplas O, Vasankari T, Vellas B, Vestbo J, Vezzani G, Vichyanond P, Viegi G, Vogelmeier C, Vontetsianos T, Wagenmann M, Wallaert B, Walker S, Wang DY, Wahn U, Wickman M, Williams DM, Williams S, Wright J, Yawn BP, Yiallouros PK, Yusuf OM, Zaidi A, Zar HJ, Zernotti ME, Zhang L, Zhong N, Zidarn M, Mercier J.
    Clin Transl Allergy. 2016
  46. Warfarin with sulfonylureas and hypoglycemic events: consider dose, length of treatment, and all sulfonylureas.
    Bosco-Lévy P, Salvo F.
    BMJ. 2016
  47. Cost Effectiveness of the Long-Acting ß2-Adrenergic Agonist (LABA)/Long-Acting Muscarinic Antagonist Dual Bronchodilator Indacaterol/Glycopyrronium Versus the LABA/Inhaled Corticosteroid Combination Salmeterol/Fluticasone in Patients with Chronic Obstructive Pulmonary Disease: Analyses Conducted for Canada, France, Italy, and Portugal.
    Reza Maleki-Yazdi M, Molimard M, Keininger DL, Gruenberger JB, Carrasco J, Pitotti C, Sauvage E, Chehab S, Price D.
    Appl Health Econ Health Policy. 2016
  48. Road traffic crash risk associated with benzodiazepine and z-hypnotic use after implementation of a colour-graded pictogram: a responsibility study.
    Orriols L, Luxcey A, Contrand B, Gadegbeku B, Delorme B, Tricotel A, Moore N, Salmi LR, Lagarde E.
    Br J Clin Pharmacol. 2016
  49. Persistence to 5-year hormonal breast cancer therapy: a French national population-based study.
    Bosco-Lévy P, Jové J, Robinson P, Moore N, Fourrier-Réglat A, Bezin J.
    Br J Cancer. 2016
  50. Vaccine Case-Population: A New Method for Vaccine Safety Surveillance.
    Théophile H, Moore N, Robinson P, Bégaud B, Pariente A.
    Drug Saf. 2016
  51. Antipsychotic long-acting injections: A community-based study from 2007 to 2014 of prescribing trends and characteristics associated with initiation.
    Verdoux H, Pambrun E, Tournier M, Bezin J, Pariente A.
    Schizophr Res. 2016
  52. Non-steroidal anti-inflammatory drugs and risk of heart failure in four European countries: nested case-control study. .
    Arfè A, Scotti L, Varas-Lorenzo C, Nicotra F, Zambon A, Kollhorst B, Schink T, Garbe E, Herings R, Straatman H, Schade R, Villa M, Lucchi S, Valkhoff V, Romio S, Thiessard F, Schuemie M, Pariente A, Sturkenboom M, Corrao G; Safety of Non-steroidal Anti-inflammatory Drugs (SOS) Project Consortium.
    BMJ. 2016
  53. Neurofeedback in Attention-Deficit/Hyperactivity Disorder: Efficacy.
    Micoulaud-Franchi JA, Salvo F, Bioulac S, Fovet T.
    J Am Acad Child Adolesc Psychiatry. 2016
  54. Highly sensitive LC-MS/MS methods for urinary biological monitoring of occupational exposure to cyclophosphamide, ifosfamide, and methotrexate antineoplastic drugs and routine application.
    Canal-Raffin M, Khennoufa K, Martinez B, Goujon Y, Folch C, Ducint D, Titier K, Brochard P, Verdun-Esquer C, Molimard M.
    J Chromatogr B Analyt Technol Biomed Life Sci. 2016